CAR-T companies are on the rise, supported by growing investment flowing into CAR-T research, landmark approvals of CAR-T cell therapies by the U.S. FDA (Kymriah and Yescarta), and major acquisitions within the CAR-T space. Most notably, Celgene snagged Juno Therapeutics for a shocking $9 billion in January 2018 and Gilead acquired Kite Pharma for an astounding … Συνεχίστε να διαβάζετε CAR-T Companies: The Meteoric Rise Of Cellular Immunotherapies.
China is home to a quarter of the world’s cancer patient population but has in previous years been behind the curve in terms of developing innovative oncology therapies. However, in just a few short years the Chinese life science industry has rapidly transformed into one of the most watched biotech hubs in the world. It’s … Συνεχίστε να διαβάζετε 6 innovative oncology biotechs in China to watch in 2018.